Progress in Target Drug Molecules for Alzheimer's Disease-Reference-Cited by-同舟云学术

Progress in Target Drug Molecules for Alzheimer's Disease

Published:2020-01-22 Issue:1 Volume:20 Page:4-36
ISSN:1568-0266
Container-title:Current Topics in Medicinal Chemistry
language:en
Short-container-title:CTMC

Author:

Xie Jiayang¹,Liang Ruirui¹,Wang Yajiang¹,Huang Junyi¹,Cao Xin²,Niu Bing¹

Affiliation:

1. School of Life Science, Shanghai University, 99 Shangda Road, Shanghai 200444, China

2. Zhongshan Hospital Institute of Clinical Science, Fudan University Shanghai Medical College, Shanghai, China

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disease that 4 widespread in the elderly. The etiology of AD is complicated, and its pathogenesis is still unclear. Although there are many researches on anti-AD drugs, they are limited to reverse relief symptoms and cannot treat diseases. Therefore, the development of high-efficiency anti-AD drugs with no side effects has become an urgent need. Based on the published literature, this paper summarizes the main targets of AD and their drugs, and focuses on the research and development progress of these drugs in recent years.

Funder

National Natural Science Foundation of China

National Key Research and Development Program of China

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference252 articles.

1. Jack C.R.; Knopman D.S.; Jagust W.J.; Shaw L.M.; Aisen P.S.; Weiner M.W.; Petersen R.C.; Trojanowski J.Q.; Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010,9(1),119-128

2. Hardy J.A.; Higgins G.A.; Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992,256(5054),184-185

3. Mohamed T.; Shakeri A.; Rao P.P.; Amyloid cascade in Alzheimer’s disease: Recent advances in medicinal chemistry. Eur J Med Chem 2016,113,258-272

4. Scheff S.W.; Price D.A.; Schmitt F.A.; DeKosky S.T.; Mufson E.J.; Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007,68(18),1501-1508

5. Rosenberg P.B.; Nowrangi M.A.; Lyketsos C.G.; Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits? Mol Aspects Med 2015,43-44,25-37

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lingguizhugan decoction ameliorates cognitive impairment in AD-like mice by influencing the microbiome–gut–brain axis mediated by SCFAs;Phytomedicine;2024-10

2. Drug–Target Interaction Prediction Based on an Interactive Inference Network;International Journal of Molecular Sciences;2024-07-15

3. Dual Inhibitors of Brain Carbonic Anhydrases and Monoamine Oxidase-B Efficiently Protect against Amyloid-β-Induced Neuronal Toxicity, Oxidative Stress, and Mitochondrial Dysfunction;Journal of Medicinal Chemistry;2024-03-04

4. Design, synthesis, in silico, and in vitro evaluation of pyrrol-2-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE/BACE 1 dual inhibitors;RSC Advances;2024

5. Design, Synthesis and Molecular Docking Study of Novel Quinolinethioacetohydrazides Bearing Α-Aminophosphonate and Their Antimicrobial Evaluation;2024